Apatinib Mesylate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

阿帕替尼 (YN968D1) 是一种多靶点酪氨酸激酶抑制剂 (TKI)，可抑制 VEGFR-2（Flk-1/KDR，IC50=1 nM）、RET、c-Kit 和 c-Src（IC50 分别为 13、429 和 530 nM） ）。

Apatinib (YN968D1) is a multitargeted tyrosine kinase inhibitor (TKI) that inhibits VEGFR-2 (Flk-1/KDR, IC50=1 nM), RET, c-Kit and c-Src (IC50=13, 429 and 530 nM respectively); significantly increases the accumulation of DOX and Rho 123 in cells overexpressing ABCB1 and ABCG2, inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ, effectively inhibits proliferation, migration and tube formation of HUVECs induced by FBS, and blocks the budding of rat aortic ring; effectively inhibits the growth of several human tumor xenograft models with little toxicity alone and in combination with chemotherapeutic agents.Gastric Cancer Approved.

——

——

YN 968D1 | YN968D1 | YN-968D1

Angiogenesis

VEGFR

VEGFR2|RET

Cancer

Gastric Cancer

1218779-75-9

493.58

C25H27N5O4S

>98% (HPLC)

DMSO: ≥ 32 mg/mL

CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4

3-Pyridinecarboxamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, methanesulfonate (1:1)

(-20℃)

With Ice Pack

≥ 2 years